Immunic is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.
Immunic is based in the Munich biotech hub Martinsried, Germany, and has subsidiaries in Halle/Saale, Germany, and Melbourne, Australia. The company currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease and psoriasis. IMU-838 is currently being tested in a phase 2b trial in patients suffering from ulcerative colitis. Additional phase 2 trials in patients with Crohn’s disease, multiple sclerosis and primary sclerosing cholangitis are planned for 2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.